Related Experiment Video
Updated: May 25, 2026
Intraductal Delivery to the Rabbit Mammary Gland
Published on: March 9, 2017
Influence of the in situ component in 389 infiltrating ductal breast carcinomas
Pau Carabias-Meseguer1, Ignacio Zapardiel, Maite Cusidó-Gimferrer
1Department of Obstetrics, Gynecology and Reproduction, Dexeus University Institute, Barcelona, Spain.
Background:
Our aim was to evaluate and compare lymph node involvement, as well as disease-free survival (DFS) and overall survival (OS), between infiltrating ductal carcinoma with (group 1) and without (group 2) intraductal carcinoma component in order to determine the prognostic value of the intraductal component.
Methods:
Data from 389 cases of infiltrating ductal carcinoma of the breast were included in the study by means of reviewing medical charts and pathology slides.
Results:
There was no statistically significant difference between both groups regarding node status. The 5-year DFS rate was 90.7% in group 1 and 81.8% in group 2 (p = 0.014), with a median follow-up of 73.2 months (95% CI 68.3-77.4). There was no statistically significant difference in 5-year OS between groups (98% group 1 vs. 93% group 2) with a median global survival of 134 months (95% CI 131-137).
Conclusions:
The presence of intraductal component in the infiltrating carcinoma seems to increase DFS and may be an independent and favorable prognostic factor for breast cancer.
